The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Unfors Raysafe AB
Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products
Forest Laboratories Inc.
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
Essar Energy plc
Advised the Independent Committee of the Board of Essar Energy plc in connection with possible offers from Essar Global Fund Limited, its 78% shareholder, for the remaining shares it does not already own and $550mm convertible bonds issued by Essar Energy plc
QR Energy, LP
Advised QR Energy, LP on the merger with Breitburn Energy Partners LP to create the largest oil-weighted MLP in the upstream oil & gas sector
Clinuvel Pharmaceuticals Limited
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases
Siemens Health Services
Advised Cerner Corporation, a leader in healthcare information services, on the acquisition of the assets of Siemens Aktiengesellschaft’s healthcare information technology business unit, Siemens Health Services, for $1.3 billion in cash.
MannKind Corporation
Advised MannKind, a biopharmaceutical company focused on the development of therapeutic products for patients with diabetes, on a collaboration with Sanofi, comprising licensing, supply and loan facility agreements with respect to licensing the Company’s lead product AFREZZA. MannKind will receive up to $925 million in upfront and milestone payments plus 35% of future profits.
NYK Ports LLC
Advised NYK Ports LLC, a leading port operating and stevedoring company, on the sale of a 49% stake to Macquarie Infrastructure Partners, a leading Australian infrastructure fund
Hiland Partners, LP
Advised Hiland Partners, a leading midstream energy company with operations primarily in the Bakken Shale, on its sale to Kinder Morgan, North America’s largest energy infrastructure company
John Laing plc
Advised Henderson Equity Partners on the initial public offering of John Laing plc, a leading originator, active investor and manager of international infrastructure projects
Refinancing of syndicated bank debt facilities
Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities
Portfolio of GlaxoSmithKline plc consumer and OTC brands
Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc
Aralez Pharmaceuticals Inc.
Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.
Niska Gas Storage Partners
Advised the Conflicts Committee of the Board of Directors of Niska and provided a fairness opinion on its sale to Brookfield
Altegra Health, Inc.
Advised Emdeon, a leading healthcare information technology company, on the acquisition of Altegra Health, a national provider of technology and intervention platforms for value-based healthcare
Allergan Generics
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
COOEC Fluor Heavy Industries Co., Ltd.
Advised Fluor Corporation on its $489 million investment for a 49% interest in a joint venture with Offshore Oil Engineering Co., Ltd. (COOEC) to own, operate and manage the Zhuhai Fabrication Yard in China’s Guangdong province
Willbros Professional Services
Advised Willbros Group, Inc. on the sale of its Professional Services segment to TRC Companies, Inc.
Aesynt, Inc.
Advised Omnicell, Inc., a leading supplier to health systems of automation solutions and business analytics software for medication and supply management, on the acquisition of Aesynt, Inc., a provider of integrated pharmacy automation solutions for hospitals and health systems
Allied Healthcare
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments
Stork
Advised Arle Capital Partners on the sale of Stork, an international provider of maintenance, modification and asset integrity services for large existing industrial facilities in the oil and gas, chemicals, industrial and power markets, to Fluor Corporation, one of the world’s largest publicly-traded engineering, procurement and construction companies
Air Warfare Destroyer Reform Strategy
Advised the Commonwealth Government of Australia as represented by the Department of Finance in relation to the Air Warfare Destroyer Reform Strategy
Antin Solar Investments
Advised Antin Infrastructure Partners on its sale of Antin Solar Investments, a leading Italian solar platform, to a consortium of investors comprised of Swiss Life Asset Management and Quercus Investment Partners
Recepta Biopharma
Advised Recepta Biopharma on a capital raise
Boehringer Ingelheim
Advised Boehringer Ingelheim, the world's largest privately held pharmaceutical company, on a global collaboration with AbbVie regarding an investigational monoclonal IL-23 antibody targeting autoimmune diseases. Within the scope of the agreement, AbbVie also acquired an option for the development and commercialisation of BI’s anti-CD-40 antibody.